CETP and atherosclerosis: Although the initial focus during the development of CETP inhibitors for reducing risk of ASCVD was on their HDL-C-raising effects, the focus is now firmly placed on their ability to lower LDL-C, non-HDL-C, and ApoB, as supported by comprehensive evidence from animal models, observational cohorts, Mendelian randomization studies, randomized controlled trials, and large meta-analyses [29•, 49, 50].